先进的基底细胞癌:对当前系统性治疗和新辅助方法的叙述性审查
Andrea Paradisi1,2, Maria Mannino1,2, Francesco Brunetti1,2
1UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endrocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
系统性疗法,如刺途径抑制剂和PD-1抗体,用于晚期基底细胞癌 (aBCC). 新辅助方法,使用手术前的全身疗法,在aBCC管理中显示出更好的结果.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 先进的基底细胞癌 (aBCC) 的治疗选择包括刺途径抑制剂 (HHI) 和抗PD-1抗体.
- 新辅助方法,包括手术前的全身疗法,越来越多地被用于aBCC.
- 这种方法旨在改善结果,特别是当手术本身可能导致重大后果时.
研究的目的:
- 审查目前针对晚期基底细胞癌的全身治疗选择.
- 总结关于aBCC管理中的新辅助方法的证据.
- 突出新辅助全身疗法的潜在好处,然后进行手术.
主要方法:
- 进行了非系统的文献综述.
- 使用PubMed作为相关研究的主要搜索引擎.
- 分析了关键的临床试验和现实生活数据.
主要成果:
- 刺途径抑制剂 (vismodegib,sonidegib) 在laBCC.中显示了60.3%和56%的客观响应率 (ORR).
- 抗PD-1抗体塞米普利马布在HHI进展的患者中显示ORR为32.1%.
- 目前正在进行的试验正在研究HHI和免疫检查点抑制剂在aBCC的新辅助设置中.
结论:
- 治疗先进的基底细胞癌仍然具有挑战性.
- 术后的新辅助方法提供了潜在的好处.
- 这一策略可以减少外科手术的复杂性,增强组织的保存,并提高患者的满意度.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
